NCT03218826
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT03419234
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel treatment 2 active_not_recruiting NCT04071236
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy treatment 1 / 2 recruiting NCT06236139
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer treatment 1 / 2 recruiting NCT06470243
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body treatment 3 recruiting NCT04550494
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations treatment 2 recruiting NCT04592237
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer treatment 2 active_not_recruiting NCT04754425
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer treatment 2 active_not_recruiting NCT03204812
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer treatment 2 completed NCT03517969
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer treatment 2 active_not_recruiting NCT04716725
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer diagnostic 2 active_not_recruiting NCT06616155
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer treatment 1 / 2 not_yet_recruiting NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV treatment 1 active_not_recruiting NCT06632977
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial treatment 2 not_yet_recruiting NCT06039371
Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study treatment 2 recruiting NCT05805371
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer No drug interventions treatment 1 recruiting NCT06145633
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer treatment 2 recruiting NCT06305598
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer treatment 1 recruiting NCT02099864
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy treatment 2 active_not_recruiting NCT03360721
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer treatment 2 active_not_recruiting NCT03873805
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer treatment 1 active_not_recruiting NCT04777071
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer diagnostic 2 recruiting NCT05960578
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study treatment 2 recruiting NCT03999515
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer treatment 2 terminated NCT05113537
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer treatment 1 / 2 recruiting NCT06526299
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease treatment 2 not_yet_recruiting NCT03751436
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer treatment 1 completed NCT06288113
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial treatment 2 recruiting NCT02893917
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer treatment 2 active_not_recruiting NCT04159896
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer treatment 2 terminated NCT05547386
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer treatment 3 completed NCT02312557
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide treatment 2 active_not_recruiting NCT05807126
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations treatment 1 withdrawn NCT02228265
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide Not Available Not Available completed NCT03805594
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer treatment 1 active_not_recruiting NCT02555189
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression treatment 1 / 2 completed NCT04951492
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma treatment 2 terminated NCT03503344
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer treatment 2 active_not_recruiting NCT01881867
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer treatment 2 completed NCT01576172
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer treatment 2 completed NCT01505868
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer treatment 1 / 2 completed NCT03516812
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer treatment 2 completed NCT05730712
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer treatment 2 recruiting NCT02598895
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway treatment 2 completed NCT04455750
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy treatment 3 active_not_recruiting NCT02703623
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer treatment 2 active_not_recruiting NCT06200103
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer treatment 2 recruiting NCT05689021
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations treatment 2 recruiting NCT05398302
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy No drug interventions diagnostic 1 recruiting NCT04693377
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial No drug interventions supportive_care Not Available recruiting NCT04616547
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones No drug interventions treatment 2 terminated NCT03217747
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies treatment 1 / 2 active_not_recruiting NCT04279561
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer diagnostic 1 terminated NCT03344211
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer treatment 2 active_not_recruiting NCT05479578
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer treatment 1 recruiting NCT03517488
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors treatment 1 completed NCT03442556
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency treatment 2 active_not_recruiting NCT02522715
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer treatment 1 / 2 active_not_recruiting NCT04033432
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer treatment 2 unknown_status NCT04388852
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers treatment 1 recruiting NCT05037500
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer treatment 1 recruiting NCT03582475
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate treatment 1 completed NCT05168618
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial treatment 2 recruiting NCT04489719
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer Not Available Not Available recruiting NCT03878524
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial treatment 1 terminated NCT03448458
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer diagnostic 2 completed NCT03406858
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer treatment 2 completed NCT04927663
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression No drug interventions diagnostic 1 recruiting NCT04471974
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer treatment 2 recruiting NCT03317392
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis treatment 1 / 2 active_not_recruiting NCT02565901
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer treatment 1 / 2 terminated NCT03456804
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer treatment 2 completed NCT05924672
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients treatment 2 not_yet_recruiting NCT03596710
Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy No drug interventions diagnostic Not Available withdrawn NCT02532114
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer treatment 1 completed NCT03709550
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer treatment 1 / 2 withdrawn